A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.


Status: Open, with recruitment

CPMS ID: 45648

IRAS ID: 282431

Research summary
Admissions to hospital and intensive care units of patients with SARS-CoV-2 pneumonia are increasing rapidly. In the UK, the mortality amongst hospital admissions is around 5.2% with case rates doubling every 2-3 days.

As COVID-19 is a new illness, we are constantly learning more about how it affects the human body. We know that the COVID-19 virus affects a number of different cells in your body, including a type of blood cell called a macrophage (immune cell), and that it can cause the number of these cells to increase in your body. To fight an infection, your immune cells produce proteins called cytokines and chemokines. These proteins can cause inflammation and at high levels can lead to damage in the tissues and organs in your body. Researchers believe this is why some people with COVID-19 infection become very ill.

In this trial, we would will randomise patients between “usual care” and “usual care + active treatment”. We plan to look at a number of different active treatments in this trial including Namilumab and Remsima (Infliximab).

If these treatments benefits people with a COVID-19 infection in this trial, the drugs will be included in another larger scale clinical trial being conducted throughout the UK, which is designed to compare treatments to find out which is the best at treating this infection.